RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

RAPT Therapeutics (Nasdaq: RAPT), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Brian Wong, M.D., Ph.D., will deliver a company overview presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.

The presentation will be accessible via live webcast, and an archived recording will be available on the company's investor relations website. RAPT Therapeutics focuses on developing novel treatments for patients with inflammatory and immunological diseases.

News Market Reaction – RAPT

-8.97%

-8.97% Session move

In the trading session that priced this news, RAPT declined 8.97%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

FAQ

When is RAPT Therapeutics presenting at the 2025 J.P. Morgan Healthcare Conference?

RAPT Therapeutics will present at the conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.

How can investors access RAPT Therapeutics' J.P. Morgan Healthcare Conference presentation?

Investors can access the live webcast and archived recording of the presentation through RAPT Therapeutics' website at investors.rapt.com/events-and-presentations.

What is RAPT Therapeutics' current development focus?

RAPT Therapeutics is focused on discovering, developing, and commercializing novel immunology-based therapies for patients with inflammatory and immunological diseases.

Who will be presenting for RAPT Therapeutics at the 2025 J.P. Morgan Healthcare Conference?

Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics, will present the company overview.